Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

• Status: Withdrawn
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently there is no significant data to support the use of pulmonary vasodilators for PAH in the setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH either at rest or during exercise. The study hypothesis is that bosentan may improve morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or exercise PAH.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rajan Saggar; University of California, Los Angeles
• Collaborator: Actelion
• Treatments: Bosentan

Criteria

Inclusion Criteria:

• Idiopathic Pulmonary Fibrosis referred for lung transplantation

• Minimum 50 meter 6 minute walk distance

• No significant underlying liver disease

Exclusion Criteria:

• Significant liver disease or cirrhosis

• non ambulatory

• previous adverse reaction/allergy to Bosentan